{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:27:39Z","timestamp":1792506459940,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.cbi.2025.111388","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T07:49:23Z","timestamp":1738136963000},"page":"111388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Sorafenib-induced cardiovascular toxicity: A cause for concern"],"prefix":"10.1016","volume":"410","author":[{"given":"Zheng","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2025.111388_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"npj Precis. Oncol."},{"issue":"10032","key":"10.1016\/j.cbi.2025.111388_bib2","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","article-title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"387","author":"Haas","year":"2016","journal-title":"Lancet"},{"issue":"36","key":"10.1016\/j.cbi.2025.111388_bib3","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.cbi.2025.111388_bib4","article-title":"Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma","volume":"18","author":"Hansen","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.cbi.2025.111388_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"Hamnvik","year":"2015","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.cbi.2025.111388_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11912-018-0708-8","article-title":"Tyrosine kinase inhibitor-induced hypertension","volume":"20","author":"Agarwal","year":"2018","journal-title":"Curr. Oncol. Rep."},{"issue":"4","key":"10.1016\/j.cbi.2025.111388_bib7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s12012-018-9499-2","article-title":"Fulminant vascular and cardiac toxicity associated with tyrosine kinase inhibitor sorafenib","volume":"19","author":"Sudasena","year":"2019","journal-title":"Cardiovasc. Toxicol."},{"issue":"5","key":"10.1016\/j.cbi.2025.111388_bib8","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1536\/ihj.17-461","article-title":"Aortic dissection and cardiac dysfunction emerged coincidentally during the long-term treatment with angiogenesis inhibitors for metastatic renal cell carcinoma","volume":"59","author":"Takada","year":"2018","journal-title":"Int. Heart J."},{"issue":"1","key":"10.1016\/j.cbi.2025.111388_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12012-009-9056-0","article-title":"Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib","volume":"10","author":"Hasinoff","year":"2010","journal-title":"Cardiovasc. Toxicol."},{"issue":"5","key":"10.1016\/j.cbi.2025.111388_bib10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.cbi.2025.111388_bib11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.hlc.2024.01.013","article-title":"Cancer therapies and cardiomyocyte viability: which drugs are directly cardiotoxic?","volume":"33","author":"Balachandran","year":"2024","journal-title":"Heart Lung Circ."},{"issue":"4","key":"10.1016\/j.cbi.2025.111388_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/diseases11040147","article-title":"Examining the effects of dasatinib, sorafenib, and nilotinib on vascular smooth muscle cells: insights into proliferation, migration, and gene expression dynamics","volume":"11","author":"Alhazzani","year":"2023","journal-title":"Diseases"},{"key":"10.1016\/j.cbi.2025.111388_bib13","article-title":"Sorafenib-associated heart failure complicated by cardiogenic shock after treatment of advanced stage hepatocellular carcinoma: a clinical case discussion","author":"Wu","year":"2017","journal-title":"Case Rep. Cardiol."},{"key":"10.1016\/j.cbi.2025.111388_bib14","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.2147\/OTT.S170138","article-title":"Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities","volume":"11","author":"Chaar","year":"2018","journal-title":"OncoTargets Ther."},{"issue":"2","key":"10.1016\/j.cbi.2025.111388_bib15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/14740338.2020.1691167","article-title":"Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?","volume":"19","author":"Furuya-Kanamori","year":"2020","journal-title":"Expet Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.cbi.2025.111388_bib16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/2047487318755193","article-title":"Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients","volume":"25","author":"Totzeck","year":"2018","journal-title":"Eur. J. Prevent. Cardiol."},{"issue":"12","key":"10.1016\/j.cbi.2025.111388_bib17","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1002\/ijc.27979","article-title":"Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis","volume":"132","author":"Qi","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.cbi.2025.111388_bib18","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40261-018-0709-2","article-title":"Cardiovascular toxicities with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of 77 randomized controlled trials","volume":"38","author":"Li","year":"2018","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.cbi.2025.111388_bib19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat Rev."},{"issue":"8","key":"10.1016\/j.cbi.2025.111388_bib20","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s00432-021-03521-w","article-title":"Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials","volume":"147","author":"Hou","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"5\u20136","key":"10.1016\/j.cbi.2025.111388_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41397-022-00279-3","article-title":"KDR genetic predictor of toxicities induced by sorafenib and regorafenib","volume":"22","author":"Quintanilha","year":"2022","journal-title":"Pharmacogenomics J."},{"issue":"4","key":"10.1016\/j.cbi.2025.111388_bib22","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s11739-024-03578-8","article-title":"Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib","volume":"19","author":"Stefanini","year":"2024","journal-title":"Intern. Emerg. Med."},{"issue":"9","key":"10.1016\/j.cbi.2025.111388_bib23","first-page":"2200","article-title":"Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study. Liver international","volume":"41","author":"Carballo-Folgoso","year":"2021","journal-title":"Off. J. Int. Associat. Stud. Liver"},{"issue":"3","key":"10.1016\/j.cbi.2025.111388_bib24","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.clnu.2017.03.026","article-title":"High fat mass associates with occurrence of targeted therapy-induced left ventricular ejection fraction reduction in patients with renal cell carcinoma","volume":"37","author":"Kazemi-Bajestani","year":"2018","journal-title":"Clin. Nutr. (Edinb.)"},{"issue":"1","key":"10.1016\/j.cbi.2025.111388_bib25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.molcel.2023.11.040","article-title":"The biochemical pathways of apoptotic, necroptotic, pyroptotic, and ferroptotic cell death","volume":"84","author":"Ai","year":"2024","journal-title":"Molecular cell"},{"issue":"6","key":"10.1016\/j.cbi.2025.111388_bib26","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s12276-021-00634-7","article-title":"Necroptosis molecular mechanisms: recent findings regarding novel necroptosis regulators","volume":"53","author":"Seo","year":"2021","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"10.1016\/j.cbi.2025.111388_bib27","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2023.5301","article-title":"Role of RIPK3-CaMKII-mPTP signaling pathway-mediated necroptosis in cardiovascular diseases","volume":"52","author":"Chen","year":"2023","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"10.1016\/j.cbi.2025.111388_bib28","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.7150\/thno.65716","article-title":"Overexpression of MFN2 alleviates sorafenib-induced cardiomyocyte necroptosis via the MAM-CaMKII\u03b4 pathway in vitro and in vivo","volume":"12","author":"Song","year":"2022","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.cbi.2025.111388_bib29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/bcpt.13318","article-title":"Cardiotoxicity of sorafenib is mediated through elevation of ROS level and CaMKII activity and dysregulation of calcium homoeostasis","volume":"126","author":"Ma","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"14","key":"10.1016\/j.cbi.2025.111388_bib30","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","article-title":"Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications","volume":"185","author":"Stockwell","year":"2022","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.cbi.2025.111388_bib31","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.cbi.2025.111388_bib32","article-title":"ATF3 promotes ferroptosis in sorafenib-induced cardiotoxicity by suppressing Slc7a11 expression","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111388_bib33","article-title":"ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis","volume":"153","author":"Jiang","year":"2022","journal-title":"Biomed. Pharmacother. = Biomed. Pharmacother."},{"issue":"7","key":"10.1016\/j.cbi.2025.111388_bib34","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.7150\/ijbs.86479","article-title":"Ferroptosis inhibitor alleviates sorafenib-induced cardiotoxicity by attenuating KLF11-mediated FSP1-dependent ferroptosis","volume":"20","author":"Li","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"40","key":"10.1016\/j.cbi.2025.111388_bib35","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1038\/onc.2017.146","article-title":"ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner","volume":"36","author":"Chen","year":"2017","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.cbi.2025.111388_bib36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41580-018-0003-4","article-title":"Mechanism and medical implications of mammalian autophagy","volume":"19","author":"Dikic","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.cbi.2025.111388_bib37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/cr.2013.168","article-title":"The machinery of macroautophagy","volume":"24","author":"Feng","year":"2014","journal-title":"Cell Res."},{"key":"10.1016\/j.cbi.2025.111388_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2022.153348","article-title":"Impaired autophagy and mitochondrial dynamics are involved in Sorafenib-induced cardiomyocyte apoptosis","volume":"481","author":"Liang","year":"2022","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.cbi.2025.111388_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145937","article-title":"Analysis of tyrosine kinase inhibitor-mediated decline in contractile force in rat engineered heart tissue","volume":"11","author":"Jacob","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.cbi.2025.111388_bib40","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.molcel.2016.02.022","article-title":"Mitofusins, from mitochondria to metabolism","volume":"61","author":"Schrepfer","year":"2016","journal-title":"Molecular cell"},{"key":"10.1016\/j.cbi.2025.111388_bib41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-pathmechdis-012419-032711","article-title":"Mitochondrial dynamics and its involvement in disease","volume":"15","author":"Chan","year":"2020","journal-title":"Ann. Rev. Pathol."},{"issue":"1","key":"10.1016\/j.cbi.2025.111388_bib42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/toxsci\/kfn157","article-title":"Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells","volume":"106","author":"Will","year":"2008","journal-title":"Toxicol. Sci. : Off. J. Soc. Toxicol."},{"issue":"4","key":"10.1016\/j.cbi.2025.111388_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23042282","article-title":"Mitochondrial toxicity associated with imatinib and sorafenib in isolated rat heart fibers and the cardiomyoblast H9c2 cell line","volume":"23","author":"Bouitbir","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.cbi.2025.111388_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030695","article-title":"ER stress responses: an emerging modulator for innate immunity","volume":"9","author":"Di Conza","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.cbi.2025.111388_bib45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12916-023-02838-2","article-title":"Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes","volume":"21","author":"Wang","year":"2023","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.cbi.2025.111388_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CAD.0b013e3283403806","article-title":"Molecular basis of hypertension side effects induced by sunitinib","volume":"22","author":"Aparicio-Gallego","year":"2011","journal-title":"Anti Cancer Drugs"},{"issue":"6","key":"10.1016\/j.cbi.2025.111388_bib47","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1161\/HYPERTENSIONAHA.119.12105","article-title":"Endothelin: 30 Years from discovery to therapy","volume":"74","author":"Barton","year":"2019","journal-title":"Hypertension (Dallas)"},{"key":"10.1016\/j.cbi.2025.111388_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115420","article-title":"Sorafenib not only impairs endothelium-dependent relaxation but also promotes vasoconstriction through the upregulation of vasoconstrictive endothelin type B receptors","volume":"414","author":"Yu","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111388_bib49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2121-10-52","article-title":"Role of ERK\/MAPK in endothelin receptor signaling in human aortic smooth muscle cells","volume":"10","author":"Chen","year":"2009","journal-title":"BMC Cell Biol."},{"issue":"19","key":"10.1016\/j.cbi.2025.111388_bib50","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.cbi.2025.111388_bib51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/ars.2013.5244","article-title":"Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress","volume":"20","author":"Lankhorst","year":"2014","journal-title":"Antioxidants Redox Signal."},{"issue":"2","key":"10.1016\/j.cbi.2025.111388_bib52","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10456-012-9327-4","article-title":"Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension","volume":"16","author":"Kruzliak","year":"2013","journal-title":"Angiogenesis"},{"issue":"4","key":"10.1016\/j.cbi.2025.111388_bib53","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41580-022-00545-z","article-title":"The physiology of alternative splicing","volume":"24","author":"Marasco","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.cbi.2025.111388_bib54","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13059-017-1286-z","article-title":"Natural genetic variation of the cardiac transcriptome in non-diseased donors and patients with dilated cardiomyopathy","volume":"18","author":"Heinig","year":"2017","journal-title":"Genome Biol."},{"issue":"4","key":"10.1016\/j.cbi.2025.111388_bib55","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7150\/ijbs.24117","article-title":"Splicing factor RBM20 regulates transcriptional network of titin associated and calcium handling genes in the heart","volume":"14","author":"Guo","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.cbi.2025.111388_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.107017","article-title":"Sorafenib induces cardiotoxicity through RBM20-mediated alternative splicing of sarcomeric and mitochondrial genes","volume":"198","author":"Liu","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"24","key":"10.1016\/j.cbi.2025.111388_bib57","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1111\/bph.14062","article-title":"Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis","volume":"174","author":"Jensen","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111388_bib58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-0-387-75681-3_7","article-title":"Beneficial effect of taurine treatment against doxorubicin-induced cardiotoxicity in mice","volume":"643","author":"Ito","year":"2009","journal-title":"Adv. Exp. Med. Biol."},{"issue":"3","key":"10.1016\/j.cbi.2025.111388_bib59","doi-asserted-by":"crossref","first-page":"H232","DOI":"10.1152\/ajpheart.00497.2014","article-title":"Role of protein phosphorylation in excitation-contraction coupling in taurine deficient hearts","volume":"308","author":"Ramila","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"4","key":"10.1016\/j.cbi.2025.111388_bib60","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/pr.2016.266","article-title":"Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease","volume":"81","author":"Suganuma","year":"2017","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.cbi.2025.111388_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173229","article-title":"The protective effect of losartan against sorafenib induced cardiotoxicity: ex-vivo isolated heart and metabolites profiling studies in rat","volume":"882","author":"Abdelgalil","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.cbi.2025.111388_bib62","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00012.2016","article-title":"The binding of captopril to angiotensin I-converting enzyme triggers activation of signaling pathways","volume":"315","author":"Reis","year":"2018","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"1","key":"10.1016\/j.cbi.2025.111388_bib63","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12872-022-02580-2","article-title":"Impact of renin-angiotensin-aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension","volume":"22","author":"Xu","year":"2022","journal-title":"BMC Cardiovasc. Disord."},{"issue":"5","key":"10.1016\/j.cbi.2025.111388_bib64","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1440-1681.2012.05699.x","article-title":"Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib","volume":"39","author":"Nagasawa","year":"2012","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"9","key":"10.1016\/j.cbi.2025.111388_bib65","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1365-2362.2002.01059.x","article-title":"Effect of Sildenafil on hypertensive lower oesophageal sphincter","volume":"32","author":"Bortolotti","year":"2002","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.cbi.2025.111388_bib66","first-page":"7","article-title":"The hypertensive effect of sorafenib is abolished by sildenafil","volume":"6","author":"Dabir\u00e9","year":"2020","journal-title":"Cardio-Oncol. (London, England)"},{"issue":"9","key":"10.1016\/j.cbi.2025.111388_bib67","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.addr.2012.01.015","article-title":"The strategic use of supramolecular pK(a) shifts to enhance the bioavailability of drugs","volume":"64","author":"Ghosh","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"38","key":"10.1016\/j.cbi.2025.111388_bib68","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1039\/C7OB01505D","article-title":"Supramolecular alleviation of cardiotoxicity of a small-molecule kinase inhibitor","volume":"15","author":"Yang","year":"2017","journal-title":"Org. Biomol. Chem."},{"issue":"4","key":"10.1016\/j.cbi.2025.111388_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/jfbc.13950","article-title":"Functionality of apigenin as a potent antioxidant with emphasis on bioavailability, metabolism, action mechanism and in vitro and in vivo studies: a review","volume":"46","author":"Kashyap","year":"2022","journal-title":"J. Food Biochem."},{"key":"10.1016\/j.cbi.2025.111388_bib70","article-title":"Protective roles of apigenin against cardiometabolic diseases: a systematic review","volume":"9","author":"Xu","year":"2022","journal-title":"Front. Nutr."},{"issue":"18","key":"10.1016\/j.cbi.2025.111388_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27186051","article-title":"The potential role of apigenin in cancer prevention and treatment","volume":"27","author":"Rahmani","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.cbi.2025.111388_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.116072","article-title":"Apigenin alleviates cancer drug Sorafenib induced multiple toxic effects in Swiss albino mice via anti-oxidative stress","volume":"447","author":"Singh","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111388_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.101920","article-title":"Apigenin enhances sorafenib anti-tumour efficacy in hepatocellular carcinoma","volume":"43","author":"Singh","year":"2024","journal-title":"Transl Oncol"},{"key":"10.1016\/j.cbi.2025.111388_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121647","article-title":"Implication of Lupeol in compensating Sorafenib-induced perturbations of redox homeostasis: a preclinical study in mouse model","volume":"322","author":"Fatma","year":"2023","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.cbi.2025.111388_bib75","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1093\/ehjci\/jead080","volume":"24","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Imag."},{"issue":"10126","key":"10.1016\/j.cbi.2025.111388_bib76","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.cbi.2025.111388_bib77","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","article-title":"Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study","volume":"35","author":"Yan","year":"2024","journal-title":"Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol."},{"issue":"20","key":"10.1016\/j.cbi.2025.111388_bib78","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cbi.2025.111388_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.116162","article-title":"A systematic comparison of anti-angiogenesis efficacy and cardiotoxicity of receptor tyrosine kinase inhibitors in zebrafish model","volume":"450","author":"Ma","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"12","key":"10.1016\/j.cbi.2025.111388_bib80","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1161\/CIRCRESAHA.111.255695","article-title":"A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity","volume":"109","author":"Cheng","year":"2011","journal-title":"Circ. Res."},{"issue":"35","key":"10.1016\/j.cbi.2025.111388_bib81","doi-asserted-by":"crossref","first-page":"37066","DOI":"10.18632\/oncotarget.5797","article-title":"Sorafenib-induced defective autophagy promotes cell death by necroptosis","volume":"6","author":"Kharaziha","year":"2015","journal-title":"Oncotarget"}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279725000183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279725000183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T09:00:32Z","timestamp":1742029232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279725000183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":81,"alternative-id":["S0009279725000183"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111388","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sorafenib-induced cardiovascular toxicity: A cause for concern","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111388"}}